Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to complete rolling NDA submission in October 2023 Conference... | June 4, 2023

Related Keywords

Canada ,United States ,Australia ,California ,Brisbane ,Queensland ,American ,Jeremy Bender ,Lindsay Kilburn ,Samuel Blackman ,Laura Cooper ,European Commission ,Head Of Communications ,Exchange Commission ,Company On Linkedin Or Twitter ,Day One Biopharmaceuticals Inc ,Globenewswire Inc ,Drug Administration ,National Medical Center ,American Society Of Clinical Oncology ,Oncology Consortium ,One Biopharmaceuticals ,Clinical Oncology ,New Drug Application ,Day One ,Response Assessment ,Neuro Oncology High Grade Glioma ,Pediatric Neuro Oncology Low Grade Glioma ,Exploratory Endpoint ,Independent Review Committee ,Pediatric Neuro Oncology Consortium ,Pacific Pediatric Neuro Oncology Consortium ,Breakthrough Therapy ,Rare Pediatric Disease ,Orphan Drug ,Private Securities Litigation Reform Act ,Sci Advisors ,Day One Biopharmaceuticals ,Nc Stock Exchange ,News ,Information ,Press Release ,Verall ,Response ,Gate ,F ,End ,Linical ,Benefit ,N ,9 ,Heavily ,Pretreated ,Valuable ,Patients ,The ,Company ,Xpects ,O ,Omplete ,Rolling ,Fda ,Submission ,October ,023 Dawn Us23954d1090 ,